Neurona raises $120M to take epilepsy cell therapy to late-stage development

Neu­rona Ther­a­peu­tics has gath­ered $120 mil­lion in what is ex­pect­ed to be its last pri­vate fi­nanc­ing round to wrap up an open-la­bel study this year and move its epilep­sy cell ther­a­py in­to a ran­dom­ized Phase II in 2025, CEO and co-founder Cory Nicholas told End­points News.

The fi­nanc­ing brings the nine-year-old biotech’s to­tal cap­i­tal haul to date to about $285 mil­lion, Nicholas said, not­ing Neu­rona will as­sess mar­ket con­di­tions about an ini­tial pub­lic of­fer­ing as its next fi­nanc­ing step.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.